Bionor Pharma – Share capital increase registered
(Oslo, Norway, 15 September 2016) Reference is made to the stock exchange announcement by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") published on 9 September 2016 regarding the extraordinary general meeting in the Company approving inter alia a share capital reduction and a share capital increase through a private placement of 525,000,000 new shares each at a par value of NOK 0.10 (the "Private Placement").
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
The share capital increase pertaining to the Private Placement has now been registered in the Norwegian Register of Business Enterprises.
Bionor's new share capital is NOK 86,066,909.70 divided into 860,669,097 shares with a par value of NOK 0.10 per share. Each share gives one vote at the Company's general meeting.
The new shares are registered in the Norwegian Central Securities Depository (the "VPS"). The new shares issued in the Private Placement will be tradable on the Oslo Stock Exchange on or about 16 September 2016.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, firstname.lastname@example.org
Jens Krøis, CFO, +45 208 01 668, email@example.com
Link to announcement in pdf